Health Insurance (Section 3C Co-Dependant Pathology Services) Amendment Determination (No. 1) 2023
I, Mary Warner, delegate of the Minister for Health and Aged Care, make the following Determination.
Dated 17 August 2023
Mary Warner
Assistant Secretary
Diagnostic Imaging and Pathology Branch
Medicare Benefits and Digital Health Division
Department of Health and Aged Care
Contents
2 Commencement
3 Authority
4 Schedules
Schedule 1—Amendments
Health Insurance (Section 3C Co-Dependent Pathology Services) Determination 2018
This instrument is the Health Insurance (Section 3C Co-Dependant Pathology Services) Amendment Determination (No.1) 2023.
(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.
Commencement information | ||
Column 1 | Column 2 | Column 3 |
Provisions | Commencement | Date/Details |
1. The whole of this instrument | 1 September 2023 |
|
Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.
(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.
This instrument is made under subsection 3C(1) of the Health Insurance Act 1973.
Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.
Health Insurance (Section 3C Co-Dependent Pathology Services) Determination 2018
1 Schedule 1 (item 72814, column 2)
Repeal the cell, substitute:
Immunohistochemical examination by immunoperoxidase or other labelled antibody techniques using the programmed cell death ligand 1 (PD‑L1) antibody of tumour material from a patient diagnosed with:
(a) non‑small cell lung cancer; or
(b) recurrent or metastatic squamous cell carcinoma of the oral cavity, pharynx or larynx; or
(c) locally recurrent unresectable or metastatic triple-negative breast cancer.